Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: A 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-Delft)

EuroIntervention

Volumn 4, Issue 1, 2008, Pages 77-83

  Meliga, Emanuele ^a,b   Garcia Garcia, Hector M ^a   Valgimigli, Marco ^c   Chieffo, Alaide ^d   Biondi Zoccai, Giuseppe ^b   Maree, Andrew O ^e   Gonzalo, Nieves ^a   Cook, Stephane ^f   Cruz Gonzalez, Ignacio ^e   Marra, Sebastiano ^b   De Servi, Stefano ^g   Palacios, Igor F ^e   Windecker, Stephan ^f   Van Domburg, Ron ^a   Colombo, Antonio ^d   Sheiban, Imad ^b   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BERN UNIVERSITY HOSPITAL   (Switzerland)

^g Ospedale Civile di Legnano   (Italy)

Author keywords

Diabetes mellitus; Drug eluting stents; Unprotected left main coronary artery disease

Indexed keywords

PACLITAXEL; RAPAMYCIN;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEFT CORONARY ARTERY; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; TARGET LESION REVASCULARISATION; TARGET VESSEL REVASCULARISATION; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG ELUTING STENT; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; REGISTER; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 57449098586     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV4I1A14     Document Type: Article

References (34)

1. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC; Ravel Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J 2004;25:107-112.
2. Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-2278.
3. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172- 1179.
4. Lincoff AM. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003;107:1556-1559.
5. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-535.
6. Kurbaan AS, Bowker TJ, Ilsley CD, Sigwart U, Richards AF; on behalf of the CABRI Investigators (Coronary Angioplasty versus Bypass Revascularization Investigation). Difference in the mortality of the CABRI diabetic and non diabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 2001;87:947-50.
7. BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996;335:217-25.
8. BARI Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35: 1122-9.
9. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary artery disease: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001;104:533- 8.
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.
11. Kastrati A, Schömig A, Elezi S, Schühlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36
12. Smith SC Jr, Faxon D, Cascio W, Schaff H, Gardner T, Jacobs A, Nissen S, Stouffer R. Prevention conference VI: diabetes and cardiovascular disease: writing group VI: revascularization in diabetic patients. Circulation 2002;105:165-9.
13. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
14. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A.Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
15. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, Ibrahim M, Schömig A, Kastrati A. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J. 2007 Oct;154(4):688-93.
16. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-1179.
17. Valgimigli M, Chieffo A, Lefèvre T, Colombo A, Morice MC, Serruys PW. Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. A pooled analysis on 340 patients treated at three European referral centres. EuroInterv. 2007;2:435-443.
18. Briguori C, Condorelli G, Airoldi F, Focaccio A, D’Andrea D, Cannavale M, Abarghouei AA, Giordano S, De Vivo F, Ricciardelli B, Colombo A. Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol. 2007 Mar 15;99(6):779-84.
19. Stankovic G, Cosgrave J, Chieffo A, Iakovou I, Sangiorgi G, Montorfano M, Airoldi F, Carlino M, Michev I, Finci L, Colombo A. Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol. 2006 Aug 1;98(3):362-6. Epub 2006 Jun 12.
20. Sakurai R, Ako J, Morino Y, Sonoda S, Kaneda H, Terashima M, Hassan AH, Leon MB, Moses JW, Popma JJ, Bonneau HN, Yock PG, Fitzgerald PJ, Honda Y; SIRIUS Trial Investigators. Predictors of edge stenosis following sirolimus-eluting stent deployment (a quantitative intravascular ultrasound analysis from the SIRIUS trial). Am J Cardiol. 2005 Nov 1;96(9):1251-3.
21. Mintz GS. Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound. Am J Cardiol. 2007 Oct 22;100(8B):26M-35M.
22. Macaya C, Garcia-Garcia HM, Colombo A, Morice MC, Legrand V, Kuck KH, Sheiban I, Suttorp MJ, Carrie D, Vrolix M, Wittebols K, Stoll HP, Donohoe D, Bressers M, Serruys PW. One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease. Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS I and ARTS I. Eurointerv. 2006;2:69-76.
23. Nicholls SJ, Tuzcu EM, Crowe T, Sipahi I, Schoenhagen P, Kapadia S, Hazen SL, Wun CC, Norton M, Ntanios F, Nissen SE. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006;47(10):1967-75.
24. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007 Feb 7;297(5):499-508.
25. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J. 2007 Jan;28(1):26-32.
26. Kumar R, Lee TT, Jeremias A, Ruisi CP, Sylvia B, Magallon J, Kirtane AJ, Bigelow B, Abrahamson M, Pinto DS, Ho KK, Cohen DJ, Carrozza JP Jr, Cutlip DE. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol. 2007 Oct 15;100(8):1187-91.
27. Orlic D, Bonizzoni E, Stankovic G, Airoldi F, Chieffo A, Corvaja N, Sangiorgi G, Ferraro M, Briguori C, Montorfano M, Carlino M, Colombo A. Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol. 2004 Apr 7;43(7):1154-60.
28. Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, Tsuchida K, Sonnenschein K, Regar E, van der Giessen WJ, de Jaegere PP, Sianos G, McFadden EP, de Feyter PJ, van Domburg RT, Serruys PW. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol. 2005 Aug 1;96(3):358-62.
29. Foster E, Zhang S, Kahn AM. Insulin stimulates arterial neointima formation in normal rats after balloon injury. Diabetes Obes Metab 2006;8:348 -351.
30. Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen BK. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 2004;286:E234 -E238.
31. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19.
32. Scheen AJ, Legrand D. Platelet dysfunction associated with insulin therapy in patients with type 2 diabetes: please do not throw the baby out with the bathwater! J Am Coll Cardiol 2007;49:628-629.
33. Rodriguez AE, Baldi J, Fernandez Pereira C, Navia J, Rodriguez Alemparte M, Delacasa A, Vigo F, Vogel D, O’Neill W, Palacios IF. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46(4):582-588.
34. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46(4):575-581.